761 related articles for article (PubMed ID: 30550232)
21. Anti-Candida albicans natural products, sources of new antifungal drugs: A review.
Zida A; Bamba S; Yacouba A; Ouedraogo-Traore R; Guiguemdé RT
J Mycol Med; 2017 Mar; 27(1):1-19. PubMed ID: 27842800
[TBL] [Abstract][Full Text] [Related]
22. Nanoscopic cell-wall architecture of an immunogenic ligand in Candida albicans during antifungal drug treatment.
Lin J; Wester MJ; Graus MS; Lidke KA; Neumann AK
Mol Biol Cell; 2016 Mar; 27(6):1002-14. PubMed ID: 26792838
[TBL] [Abstract][Full Text] [Related]
23. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
[No Abstract] [Full Text] [Related]
24. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth.
Cateau E; Rodier MH; Imbert C
J Antimicrob Chemother; 2008 Jul; 62(1):153-5. PubMed ID: 18407917
[TBL] [Abstract][Full Text] [Related]
25. Natural products targeting the synthesis of β(1,3)-D-glucan and chitin of the fungal cell wall. Existing drugs and recent findings.
Curto MÁ; Butassi E; Ribas JC; Svetaz LA; Cortés JCG
Phytomedicine; 2021 Jul; 88():153556. PubMed ID: 33958276
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.
Sun Q; Xiong K; Yuan Y; Yu J; Yang L; Shen C; Su C; Lu Y
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791942
[TBL] [Abstract][Full Text] [Related]
27. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.
Lee KK; Maccallum DM; Jacobsen MD; Walker LA; Odds FC; Gow NA; Munro CA
Antimicrob Agents Chemother; 2012 Jan; 56(1):208-17. PubMed ID: 21986821
[TBL] [Abstract][Full Text] [Related]
28. Fungicidal activity and morphological alterations of Candida albicans induced by echinocandins: study of strains with reduced caspofungin susceptibility.
Dunyach C; Drakulovski P; Bertout S; Jouvert S; Reynes J; Mallié M
Mycoses; 2011 Jul; 54(4):e62-8. PubMed ID: 20113400
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms.
Kovács R; Nagy F; Tóth Z; Bozó A; Balázs B; Majoros L
Lett Appl Microbiol; 2019 Oct; 69(4):271-278. PubMed ID: 31385615
[TBL] [Abstract][Full Text] [Related]
30. A comparative evaluation of properties and clinical efficacy of the echinocandins.
Kim R; Khachikian D; Reboli AC
Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730
[TBL] [Abstract][Full Text] [Related]
31. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.
Wiederhold NP; Najvar LK; Bocanegra RA; Kirkpatrick WR; Patterson TF
Antimicrob Agents Chemother; 2011 Jul; 55(7):3254-60. PubMed ID: 21502632
[TBL] [Abstract][Full Text] [Related]
32. Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity.
Taft CS; Stark T; Selitrennikoff CP
Antimicrob Agents Chemother; 1988 Dec; 32(12):1901-3. PubMed ID: 2977537
[TBL] [Abstract][Full Text] [Related]
33. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.
Stevens DA; Ichinomiya M; Koshi Y; Horiuchi H
Antimicrob Agents Chemother; 2006 Sep; 50(9):3160-1. PubMed ID: 16940118
[TBL] [Abstract][Full Text] [Related]
34. Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungin.
Toutounji M; Tokajian S; Khalaf RA
Fungal Genet Biol; 2019 Jun; 127():12-22. PubMed ID: 30794951
[TBL] [Abstract][Full Text] [Related]
35. Antifungal Activity Directed Toward the Cell Wall by 2-Cyclohexylidenhydrazo- 4-Phenyl-Thiazole Against Candida albicans.
de Sá NP; Pôssa AP; Perez P; Ferreira JMS; Fonseca NC; Lino CI; Cruz LB; de Oliveira RB; Rosa CA; Borelli BM; Mylonakis E; Fuchs BB; Johann S
Infect Disord Drug Targets; 2019; 19(4):428-438. PubMed ID: 29852876
[TBL] [Abstract][Full Text] [Related]
36. The Paradoxical Effect of Echinocandins in Aspergillus fumigatus Relies on Recovery of the β-1,3-Glucan Synthase Fks1.
Loiko V; Wagener J
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872079
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin and caspofungin show synergistic antifungal effects in caspofungin-susceptible and caspofungin-resistant Candida strains in vitro.
Lefranc M; Accoceberry I; Fitton-Ouhabi V; Biteau N; Noël T
J Antimicrob Chemother; 2024 Jan; 79(1):151-156. PubMed ID: 37991226
[TBL] [Abstract][Full Text] [Related]
38. Puf4 Mediates Post-transcriptional Regulation of Cell Wall Biosynthesis and Caspofungin Resistance in Cryptococcus neoformans.
Kalem MC; Subbiah H; Leipheimer J; Glazier VE; Panepinto JC
mBio; 2021 Jan; 12(1):. PubMed ID: 33436441
[TBL] [Abstract][Full Text] [Related]
39. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
40. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
